8-K: Matinas BioPharma Announces 1-for-50 Reverse Stock Split and Share Reduction

Matinas BioPharma has announced a 1-for-50 reverse stock split and a reduction in authorized shares, effective August 30, 2024, to maintain NYSE American listing compliance.

Summary

• Matinas BioPharma's board has approved a 1-for-50 reverse stock split of its common stock.
• The company will also reduce the total number of authorized shares from 500,000,000 to 250,000,000.
• The reverse stock split and share reduction will be effective on August 30, 2024, at 5:00 PM EST.
• Trading on a split-adjusted basis is expected to begin on September 3, 2024, under the existing ticker symbol MTNB.
• The new CUSIP number will be 576810 303.
• Stockholders will receive one whole share for every 50 shares they own, with fractional shares rounded up to the nearest whole share.
• The company aims to maintain compliance with NYSE American listing standards through these actions.
• The company may consider uplisting to The Nasdaq Global Market in the future, which requires a minimum bid price of $4.00 per share initially and $1.00 per share ongoing.

Sentiment

Score: 5

Explanation: The document describes a necessary but potentially risky action to maintain listing compliance. While the company is taking steps to improve its position, the outcome is not guaranteed, leading to a neutral sentiment.

Positives

• The reverse stock split is intended to help maintain compliance with NYSE American listing standards.
• The company may consider uplisting to The Nasdaq Global Market in the future, which could increase visibility and attract new investors.
• Stockholders will receive whole shares, with fractional shares rounded up, avoiding any cash payments for fractional shares.

Negatives

• There is no guarantee that the reverse stock split will enable the company to maintain its listing on the NYSE American.
• The company cannot assure that it will pursue a listing on The Nasdaq Global Market or that it will meet the minimum bid price requirements if it does.
• The reverse stock split will reduce the number of shares outstanding, which could be perceived negatively by some investors.

Risks

• There is a risk that the reverse stock split may not be sufficient to maintain compliance with NYSE American listing standards.
• The company may not be able to meet the listing requirements for The Nasdaq Global Market.
• The reverse stock split could negatively impact investor sentiment.

Future Outlook

The company may consider uplisting to The Nasdaq Global Market in the future, but there is no guarantee that this will occur or that the company will meet the listing requirements.

Management Comments

• The company anticipates that the effect of the Reverse Stock Split will be sufficient to maintain compliance with the NYSE Americans continued listing standards.
• The company may in the future consider targeting The Nasdaq Global Market or another tier of The Nasdaq Stock Market for uplisting of the Common Stock.

Industry Context

Reverse stock splits are often used by companies to increase their share price and maintain listing compliance, particularly when facing delisting risks. This action is not uncommon in the biotech sector, where companies may experience volatility in their stock price.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism for companies facing delisting from major exchanges, such as the NYSE American.
• Many biotech companies with low share prices have used reverse stock splits to regain compliance with listing requirements.
• For example, companies like Agenus Inc. and Ocugen Inc. have recently implemented reverse stock splits to maintain their Nasdaq listings.
• The 1-for-50 ratio is a relatively high ratio, indicating a significant need to increase the share price to meet listing requirements.

Stakeholder Impact

• Shareholders will have their number of shares reduced by a factor of 50, but their percentage ownership will remain the same.
• The reverse stock split is intended to maintain the company's listing on the NYSE American, which is important for investor confidence.
• The potential uplisting to The Nasdaq Global Market could attract new investors and increase the company's visibility.

Next Steps

• The reverse stock split and share reduction will be implemented on August 30, 2024.
• Trading on a split-adjusted basis will begin on September 3, 2024.
• The company may consider uplisting to The Nasdaq Global Market in the future.

Key Dates

Keywords

reverse stock split, authorized share reduction, NYSE American, Nasdaq Global Market, listing compliance, stock split, MTNB, Matinas BioPharma